Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters







Language
Year range
1.
Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012
Souza, Carmino Antonio de; Pagnano, Katia Borgia Barbosa; Bendit, Israel; Conchon, Monika; Freitas, Carla Maria Boquimpani de Moura; Coelho, Arthur Moellmann; Funke, Vaneuza Araújo Moreira; Bernardo, Wanderley Marques.
Rev. bras. hematol. hemoter ; 34(5): 367-382, 2012. tab
Article in English | LILACS | ID: lil-654979

Subject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy
2.
Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
Conchon, Monika; Freitas, Carla Maria Boquimpani de Moura; Rego, Maria Aparecida do Carmo; Braga Junior, José Wilson Ramos.
Rev. bras. hematol. hemoter ; 33(2): 131-139, 2011. ilus, tab
Article in English | LILACS | ID: lil-596303

ABSTRACT

Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.


Subject(s)
Humans , Drug Resistance , Drug-Related Side Effects and Adverse Reactions , Interferon-alpha/administration & dosage , Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Protein Kinase Inhibitors , Piperazines/therapeutic use , Gastrointestinal Tract
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL